Salute e Benessere

Orexo strengthens its sustainability work by establishing a social financing…

Proceeds from any Social Financing Instruments are fully dedicated to the financing of projects with a positive social impact and expected to help advance the following SDG and targets, as further described in the Social Framework: Proceeds from any Social Financing Instruments are fully dedicated to the financing of projects with a positive social impact and expected to help advance the following SDG and targets, as further described in the Social Framework: Morningstar Sustainalytics has...

Orexo contemplates issuance of senior secured callable floating rate social…

The Tender Offer expires at the later of 16.00 CET on March 14, 2024, and the pricing date of the New Social Bonds, which will be announced by the Company in connection therewith, unless extended, shortened, re-opened, withdrawn, or terminated at the sole discretion of the Company (the "Expiration Date"). Settlement of the Tender Offer is expected to occur approximately ten business days after the Expiration Date. The Company will, in connection with the allocation of the New Social…

Nippon Express (Deutschland) and Nippon Express (Middle East) Participate in…

Exhibit booth: https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202403047471/_prw_PI2fl_W39pwsxa.png Exhibit booth:https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202403047471/_prw_PI2fl_W39pwsxa.png NX representatives at booth:https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202403047471/_prw_PI3fl_MhT5v18F.png Arab Health 2024 is one of the world's largest international healthcare trade shows. In line with this year's theme of "Connecting Minds, Transforming...

Crossject gender equality score reaches 96/100 in 2024

Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations,today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%.The Gender Equality Index is a tool to measure the progress of gender equality in the EU, giving more visibility to areas that need improvement and ultimately supporting...

dsm-firmenich completes the divestiture of its Jiangshan Vitamin C plant in…

Financial details of the transaction were not disclosed. Financial details of the transaction were not disclosed. For more information, please contact:dsm-firmenich media enquiries:media@dsm-firmenich.com dsm-firmenich investor relations enquiries:investors@dsm-firmenich.com About dsm-firmenich As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to...

Mithra reports full year 2023 financial results

Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from partnerships.Product sales were EUR 18.7 million, up +19.3% vs EUR 15.7 million in 2022.ESTELLE® product sales reached EUR 10.4 million in 2023 beating the September 2023 guidance of EUR 8.5 million and up from EUR 9.2 million in 2022.Cash position, at EUR 9.0 million at end of 2023,...

Hyloris to Report 2023 Full-Year Results on 14 March 2024

Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET. Following the release, the company will host a live webcast to discuss 2023 results and the outlook for 2024. Participants will...

Ultimovacs ASA: Mandatory notification of trade by primary insiders

Watrium AS, a closely related party of Haakon Stenrød, a board member and primary insider in Ultimovacs ASA, has today sold 1,780,575 shares in the company at an average price of NOK 9.6718 per share. Following these transactions, Watrium AS and closely related parties hold 0 shares in Ultimovacs ASA.This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.Attachments ...

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

DBV Technologies Reports Full Year 2023 Financial Results and Business UpdateAdvanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on...

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

About BioVaxys Technology Corp. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), a biopharmaceuticals company registered inBritish Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other...

Inventiva announces that screening in the NATiV3, Phase III, clinical trial…

Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.Screening of patients is resuming in sites operating under central IRB in the US. Other sites and countries are expected to resume screening and randomization activities progressively over the next weeks. Last Patient First Visit is currently targeted for first half 2024. Daix (France), Long Island...

HKBU research suggests potential of artemisinin derivative in treating human…

Artesunate as an anti-obesity agent Artesunate as an anti-obesity agent The treatment of obesity typically involves a combination of lifestyle changes and medications. However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects. Artesunate is an FDA-approved anti-malaria drug. Previous studies have unveiled another beneficial effect of artesunate in reducing body weight in obese mice, but the mechanism...

Multi-Billion Opportunities in the US Nursing Care Market, the Market to…

To Know More, Download the Free Sample Report: https://www.focusreports.store/request-sample/us-nursing-care-market-focused-insights To Know More, Download the Free Sample Report: https://www.focusreports.store/request-sample/us-nursing-care-market-focused-insights The U.S. Nursing Care Market Report Scope The US is the largest revenue contributor to the global nursing care market. The South region of the US accounted for the highest market growth for nursing care. The presence...

Oxurion Receives Transparency Notification from Atlas Special Opportunities…

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 07, 2024 – 07:00 PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on March 06, 2024, from Atlas Special Opportunities, LLC indicating that as of March 01, 2024, it...

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of February 29, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (March 7, 2024 - 6:30 pm)– As of February 29, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses,...

EssilorLuxottica and Dolce&Gabbana announce 16-year licensing renewal

EssilorLuxottica and Dolce&Gabbana announce 16-year licensing renewalCharenton-le-Pont, France and Milan, Italy (March 7, 2024)- EssilorLuxottica and Dolce&Gabbana, today, announce the early renewal of their licensing agreement for the development, production and worldwide distribution of prescription frames and sunglasses under the Dolce&Gabbana brand.The existing agreement, which took effect on January 1, 2020, and was scheduled to expire on December 31, 2029, has been...

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)29 February 202483,814,526Gross...

Dental 3D Printing Market Size to Grow USD 1328.2 Million by 2030 at a CAGR of…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-1L813/Global_Dental_3D_Printing_Market_Insights_and_Forecast_to_2028 Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-1L813/Global_Dental_3D_Printing_Market_Insights_and_Forecast_to_2028 Major Factors Driving the Growth of the 3d Dental Printing Market The 3D dental printing industry is expanding due to a number of important factors. First off, technological developments have produced...

RIMOWA ANNOUNCES JAY CHOU AS GLOBAL AMBASSADOR

In the latest announcement, the multitalented musician, director and actor embodies RIMOWA's spirit of craftsmanship and innovation. With a career trajectory marked by constant exploration and reinvention, the artist's values mirror RIMOWA's commitment to constantly pushing boundaries and setting new standards. In his new role as RIMOWA's global ambassador, Jay Chou is set to inspire travelers around the globe to embark on their own life-changing journeys. "At RIMOWA, we have always…

Biomaterials Market Worth $64.2 billion | MarketsandMarkets™

Browse in-depth TOC on "Biomaterials Market" Browse in-depth TOC on "Biomaterials Market" 908 - Tables 50 - Figures 698 - Pages Biomaterials Market Scope: Metallic biomaterials segment accounted for the largest estimated share of the biomaterials market Based on type, the biomaterials market is segmented into metallic (stainless steel, titanium & titanium alloys, cobalt-chrome alloys, gold, silver, magnesium, and other metallic biomaterials), polymeric...

Smart Packaging Innovation Pushes Ophthalmic Market to $527.8 Million by 2034

An ophthalmic drug is a medication specifically designed to be applied to the eye. These drugs come in various forms, including eye drops, ointments, gels, and inserts, and address a wide range of eye conditions, from common issues like dry eyes and allergies to more serious problems like glaucoma and infections. Due to the sensitive nature of the eye, these medications are formulated and delivered with special care to ensure effectiveness and safety. An ophthalmic drug is a medication...

AB Science provides a summary of the live webcast held on March 4, 2024 giving…

PRESS RELEASESUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENTParis, March 7, 2024, 3pm CETAB Science SA(Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development. The webcast presentation is available on the company's website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ The presentation covered four...

Accumulus Synergy Adds Two World-Class Executives to Its Leadership Team

“I am thrilled to add Chanille and Kevin to our team,” said Francisco Nogueira, Accumulus CEO. “We are propelling the life sciences-regulatory ecosystem toward more data-driven solutions, which requires innovation and a commitment to security. Chanille has a tremendous track record in bringing data-centric information exchange products to market in regulated industries and Kevin has decades of cybersecurity experience including roles with the Department of Health and Human Services,...

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative…

®have been sold in Italy. PYLCLARI ®(INN: Piflufolastat ( 18 F)) also known as ( 18 F)-DCFPyL, is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on...

Altri Comunicati